ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 2.7 | 2.6 | 2.6 |
| Other income | 0.1 | 0.1 | 0.1 |
| Total income | 2.8 | 2.7 | 2.7 |
| Profit before exceptional items & tax | 0.4 | 0.5 | 0.3 |
| Profit before tax | 0.4 | 0.5 | 0.3 |
| Net profit | 0.3 | 0.3 | 0.2 |
| Operating margin | 14.3% | 18.5% | 11.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +50.00% |
|---|---|
| Net profit, quarter on quarter | +0.00% |
| Revenue, year on year | +3.80% |
| Operating profit, year on year | +50.00% |
| Operating profit, quarter on quarter | -25.00% |
BSE results filing, NSE: TEJNAKSH. Figures extracted from the filing.
Tejnaksh Healthcare Ltd: key numbers
- Share price
- ₹13.25
- Market cap
- ₹26.92 Cr
- Revenue (annual)
- ₹10.79 Cr
- Net profit (annual)
- ₹1.23 Cr
- P/E (TTM)
- 21.8×Sector 54.5×
- Promoter holding
- 73.83%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tejnaksh Healthcare Ltd
All →Tejnaksh Healthcare Board Meeting Date
Tejnaksh Healthcare will hold a board meeting on 12 November 2026 to consider unaudited Q2 standalone and consolidated results. The filing also notes the trading window closure.
Tejnaksh Healthcare Business Update
Tejnaksh Healthcare's Managing Director Dr. Ashish Rawandale-Patil was selected as a mentor for ES-TIP 2027. The honour is an international recognition of his medical innovation expertise.
Tejnaksh Healthcare Business Update
Tejnaksh Healthcare announced publication of a multicentric validation study of its Pflow device in the Indian Journal of Urology. The filing is a scientific publication update with no financial value.
Tejnaksh Healthcare Other Announcement
Tejnaksh Healthcare Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of SEBI LODR.
Tejnaksh Healthcare Management Change
Tejnaksh Healthcare shareholders approved the re-appointment of Mr. Suhas Vasantrao Thorat as an Independent Director for a second five-year term at the 18th Annual General Meeting.
Tejnaksh Healthcare Annual General Meeting
The company issued a notice for its Annual General Meeting scheduled for September 29, 2026, to consider financial statements, director appointments, and related party transaction approvals.